Normal infant after treatment of acute myeloid leukaemia in pregnancy with daunorubicin.
Daunorubicin, thioguanine and cytosine arabinoside were administered from the 17th to 34th weeks of pregnancy in a 23-year-old patient with acute myeloid leukaemia. The patient went into remission of her leukaemia, and a normal male infant was born after labour was induced in the 40th week. This experience supports the view that modern regimens of anti-leukaemic drugs may be administered during the second and third trimesters of pregnancy without harmful effects on the foetus.
D000328:Adult; D003596:Cytosine / Q000627:therapeutic use; D003630:Daunorubicin / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005333:Fetus / Q000187:drug effects*; D006801:Humans; D007231:Infant, Newborn; D007751:Labor, Induced; D015470:Leukemia, Myeloid, Acute / Q000150:complications* / Q000188:drug therapy; D008297:Male; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third; D013866:Thioguanine / Q000627:therapeutic use
D003596:Cytosine; D013866:Thioguanine; D003630:Daunorubicin